When serious things go wrong with a trial, such as an adverse event or an incident report is filed, it is easier for project managers to identify a problem that needs to be addressed in a trial.
When serious things go wrong with a trial, such as an adverse event or an incident report is filed, it is easier for project managers to identify a problem that needs to be addressed in a trial. However, it is the unanticipated and less obvious situations that happen throughout the trial that can put it at risk.
Mark Hronec, Director of PriceWaterhouseCoopers, noted during a December 2013 webinar sponsored by SAS and Applied Clinical Trials titled Myths, Models and Momentum: Risk-Based Monitoring this exact situation. He termed them traditional and non-traditional risk factors. Along the traditional were those previously mentioned—recruitment rates, protocol deviations, serious adverse events, the drug safety profile or the site location or experience at the site. However, those non-traditional risks that could be identified and leveraged using real-time “big data” predictors included average patient visit window deviation, the number of visits the site has per day, the number of inclusion or exclusion criteria, the length of the informed consent form, among others.
Many questions in the webinar were centered on risk-determinations. Laurie Rose, Principal Industry Consultant, Health & Life Sciences at SAS, recommended using historical data, information on past site performance or country and regional numbers; sites that perform better with recruitment, enrollment, and actual study startup. “[With those data, you are] using a predictive model rather than just summarizing and putting then all together. Using a predictive model can help determine basically a better set of expectations of what might come in the future.” Rose also noted other predictive data would include working within the same therapeutic area or other similar compounds from past studies and going to future studies where data is available, but the clinical data and that operational data will be helpful in looking at the next study coming up.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.